Founded

Address

Other Office
285 Riverside Avenue
Suite 250
Westport, CT 06880
United States

Open map


Recent investment activity

KANDO id: 30845

Corporate information

Registration country

Company type

Venture capital firm with a focus on early stage technology and healthcare companies

Funds managed

Fund Type Vintage Currency Committed capital IRR x
Canaan IX LP Venture 2012
Canaan VIII LP Venture 2007 14.50 % 1.62 x
Canaan Equity Partners VII Venture 2005 20.70 % 3.10 x

Funding rounds

Top investment portfolio themes
software (4)  
fintech (2)  
insurance (2)  
sensors (1)  
blockchain (1)  

Actual initial investment stage
N/A (5)
Seed (1)

Investment activity status
Active investor

Selected investments

Displaying 1 - 25 of 242
Profile Country Date Funding
0-In Design Automation Inc Provider of verification products that help verify multi-million gate ASICs and SOC designs. N/A
3Crowd Technologies Series A
Active Network Inc Series F
Active Network Inc N/A
Active Network Inc Series E
Active Network Inc Series D
Adlyfe Series A
Advanced BioHealing Inc An industry leader in the science of regenerative medicine Series C
Advanced BioHealing Inc An industry leader in the science of regenerative medicine Series B
Aldea Pharmaceuticals Inc Venture
Altheos Inc A drug development company focused on next generation intraocular pressure (IOP) lowering agents for glaucoma and ocular hypertension. Series A
Amicus Therapeutics Inc N/A Initial investment
Aperto Networks Inc WiMax equipment company. Series F
Aperto Networks Inc WiMax equipment company. Series E
Aperto Networks Inc WiMax equipment company. Series D
Aperto Networks Inc WiMax equipment company. Series C
Apieron Inc Asthma Device Monotoring Maker Series D
Apieron Inc Asthma Device Monotoring Maker Series C
Arbor Networks Inc DDoS attack prevention, network security and visibility solutions company. N/A Initial investment
Argon Networks Inc N/A
Associated Content Inc Content Publishing Platform Series B
Associated Content Inc Content Publishing Platform Series C
BiPar Sciences Inc Biopharmaceutical company developing and commercializing tumor-selective drugs for cancer patients. Series C
BiPar Sciences Inc Biopharmaceutical company developing and commercializing tumor-selective drugs for cancer patients. Series B
BiPar Sciences Inc Biopharmaceutical company developing and commercializing tumor-selective drugs for cancer patients. Series A

Selected Products / Customers

Financials